Nanopatch for more effective vaccination

Drug delivered: Vaccines (influenza, HPV, etc.)
Innovation: Low-dose, simplified vaccine delivery
Research organization: University of Queensland

When it comes to vaccines, simple and effective delivery has a very practical purpose: to get more drugs to more people.

And when researchers in Australia showed earlier this year that they had a working model of a vaccine patch with thousands of coated nanospikes, the industry listened. Merck ($MRK) presented the preclinical device with a three-year grant, as its lead engineer, Mark Kendall, pushes for human trials.

By dispensing with the needle and syringe developed all the way back in 1853, according to a Reuters report, the nanopatch allows for a much smaller dose, zero refrigeration and a muscle delivery that reduces contact with immune cells. Plus, for many, pain does play a factor in whether they get vaccinated.

Nanopatch for more effective vaccination

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.